Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
Xavier Montalbán, Christine Lebrun‐Frénay, Jiwon Oh, Georgina Arrambide, Marcello Moccia, Maria Pia Amato, Lilyana Amezcua, Brenda Banwell, Amit Bar-Or, Frederik Barkhof, Helmut Butzkueven, Olga Ciccarelli, Jeremy Chataway, Jeffrey A. Cohen, Giancarlo Comi, Jorge Correale, Florian Deisenhammer, Massimo Filippi, Julie Fiol, Mark S. Freedman, Kazuo Fujihara, Cristina Granziera, Ari Green, Hans-Peter Hartung, Kerstin Hellwig, L Kappos, Dorlan Kimbrough, Joep Killestein, Fred Lublin, Romain Marignier, Ruth Ann Marrie, Aaron Miller, Susana Otero-Romero, Daniel Ontaneda, Sudarshini Ramanathan, Daniel Reich, Maria A. Rocca, Àlex Rovira, Shiv Saidha, Amber Salter, Jaume Sastre‐Garriga, Deanna Saylor, Andrew Solomon, Maria Pia Sormani, Bruno Stankoff, Mar Tintoré, Helen Tremlett, Anneke van der Walt, Shanthi Viswanathan, Heinz Wiendl, Brigitte Wildemann, Bassem Yamout, Paola Zaratin, Peter A. Calabresi, Timothy Coetzee, Alan J. Thompson (2025). Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. , 24(10), DOI: https://doi.org/10.1016/s1474-4422(25)00270-4.
Article19 days agoRelapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014)
Massimo Filippi, Jon Riolo, Jeffrey A. Cohen, Hans‐Peter Hartung, Xavier Montalbán, Sven G. Meuth, Léorah Freeman, Tanuja Chitnis, Cristina Granziera, Erik DeBoer, Chun-Yen Cheng, Jennifer Reardon, Chahin Pachaï, James K. Sheffield, Bruce Cree, Ludwig Kappos (2024). Relapse-associated Worsening and Progression-independent Relapse Activity in Ozanimod-treated Participants with Relapsing Multiple Sclerosis from the RADIANCE and DAYBREAK Trials (P6-6.014). , 102(7_supplement_1), DOI: https://doi.org/10.1212/wnl.0000000000204935.
Article19 days agoClinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007)
Timothy R. Vollmer, G. Comi, Peter Sørensen, Douglas L. Arnold, Massimo Filippi, О. А. Статінова, Tetyana Kobys, E. Becker, Diane L. Jeffery, Xavier Montalbán, Ludwig Kappos, Krzysztof Selmaj, Frauke Zipp, Eva Havrdová, Jeffrey A. Cohen (2012). Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007). , 78(Meeting Abstracts 1), DOI: https://doi.org/10.1212/wnl.78.1_meetingabstracts.s01.007.
Article19 days agoDiagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman, Stephen C. Reingold, Brenda Banwell, M. Clanet, Jeffrey A. Cohen, Massimo Filippi, Kazuo Fujihara, Eva Havrdová, Michael Hutchinson, Ludwig Kappos, Fred Lublin, Xavier Montalbán, Paul O’Connor, Magnhild Sandberg‐Wollheim, Alan J. Thompson, Emmanuelle Waubant, Brian G. Weinshenker, Jerry S. Wolinsky (2011). Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. , 69(2), DOI: https://doi.org/10.1002/ana.22366.
Article19 days agoAlemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001)
Sven Schippling, Jeffrey A. Cohen, Alasdair Coles, D. A. S. Compston, Edward Fox, Massimo Filippi, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Frederik Barkhof, David Margolin, Karthinathan Thangavelu, Douglas L. Arnold (2016). Alemtuzumab-Treated Patients with RRMS Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years Despite Most Being Treatment-Free for 4 Years: CARE-MS I and II Extension Study (S51.001). , 86(16_supplement), DOI: https://doi.org/10.1212/wnl.86.16_supplement.s51.001.
Article19 days ago